Hrt Financial LP Vir Biotechnology, Inc. Transaction History

Hrt Financial LP

$12.8 Billion
Q1 2025

A detailed history of Hrt Financial LP transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 15,583 shares of VIR stock, worth $70,902. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,583

Previous 84,049 81.46%

Holding current value

$70,902

Previous $616,000 83.77%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$6.48 - $12.48 $443,659 - $854,455	-68,466 Reduced 81.46%	15,583 $100,000
Q4 2024 Feb 14, 2025	BUY	$6.74 - $10.17 $236,081 - $356,224	35,027 Added 71.45%	84,049 $616,000
Q3 2024 Nov 12, 2024	BUY	$7.26 - $10.7 $99,578 - $146,761	13,716 Added 38.85%	49,022 $367,000
Q2 2024 Aug 12, 2024	BUY	$7.63 - $12.66 $269,384 - $446,973	35,306 New	35,306 $314,000
Q4 2023 Feb 09, 2024	BUY	$7.76 - $10.29 $474,097 - $628,667	61,095 New	61,095 $614,000
Q1 2023 May 12, 2023	BUY	$22.26 - $30.85 $2.63 Million - $3.64 Million	118,011 New	118,011 $2.75 Million
Q2 2022 Aug 12, 2022	SELL	$19.08 - $26.7 $481,846 - $674,281	-25,254 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $535,132 - $1.01 Million	25,254 New	25,254 $649,000
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $717,474 - $1.12 Million	-20,558 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$38.75 - $51.0 $1.28 Million - $1.69 Million	-33,080 Reduced 61.67%	20,558 $971,000
Q1 2021 May 17, 2021	BUY	$26.34 - $83.07 $1.41 Million - $4.46 Million	53,638 New	53,638 $2.75 Million

Others Institutions Holding VIR

# of Institutions

251

Shares Held

91.5M

Call Options Held

257K

Put Options Held

261K

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $604M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account